| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yuechen Luo, Wenwen Li, Gang Yu, Juan Yu, Ling Han, Ting Xue, Zhina Sun, Song Chen, Chunming Fang, Chunxiao Zhao, Qing Niu, Fei Yang, Zhongchao Han, Tao Cheng, Yun Zeng, Fang Liao, Guogang Xu, Xiaoming Fen. Tsc1 expression by dendritic cells is required to preserve T-cell homeostasis and response. Cell death & disease. vol 8. issue 1. 2017-10-26. PMID:28079897. |
recent evidence highlights a critical role of tuberous sclerosis complex 1 (tsc1), a primarily upstream negative regulator of mammalian target of rapamycin (mtor), in dc development, but whether and how tsc1 directly regulate mature dc function in vivo remains elusive. |
2017-10-26 |
2023-08-13 |
Not clear |
| Atsushi Sat. mTOR, a Potential Target to Treat Autism Spectrum Disorder. CNS & neurological disorders drug targets. vol 15. issue 5. 2017-10-04. PMID:27071790. |
autism spectrum disorder (asd) is frequently accompanied by monogenic disorders, such as tuberous sclerosis complex, phosphatase and tensin homolog tumor hamartoma syndrome, neurofibromatosis 1, and fragile x syndrome, in which mtor is hyperactive. |
2017-10-04 |
2023-08-13 |
Not clear |
| Michael A Cardis, Cynthia Marie Carver DeKlot. Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role. Archives of disease in childhood. vol 102. issue 9. 2017-09-18. PMID:28351834. |
tuberous sclerosis complex (tsc) is a multisystem genetic disorder stemming from unregulated activation of the mammalian target of rapamycin (mtor) pathway, resulting in the growth of hamartomas in multiple organs. |
2017-09-18 |
2023-08-13 |
Not clear |
| Juxiang Cao, Magdalena E Tyburczy, Joel Moss, Thomas N Darling, Hans R Widlund, David J Kwiatkowsk. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. The Journal of clinical investigation. vol 127. issue 1. 2017-09-06. PMID:27918305. |
tuberous sclerosis complex (tsc) is an autosomal dominant tumor-suppressor gene syndrome caused by inactivating mutations in either tsc1 or tsc2, and the tsc protein complex is an essential regulator of mtor complex 1 (mtorc1). |
2017-09-06 |
2023-08-13 |
human |
| Lauren E McLane, Jennifer N Bourne, Angelina V Evangelou, Luipa Khandker, Wendy B Macklin, Teresa L Woo. Loss of Tuberous Sclerosis Complex1 in Adult Oligodendrocyte Progenitor Cells Enhances Axon Remyelination and Increases Myelin Thickness after a Focal Demyelination. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 37. issue 31. 2017-08-22. PMID:28694334. |
although the mammalian target of rapamycin (mtor) is an essential regulator of developmental oligodendrocyte differentiation and myelination, oligodendrocyte-specific deletion of tuberous sclerosis complex (tsc), a major upstream inhibitor of mtor, surprisingly also leads to hypomyelination during cns development. |
2017-08-22 |
2023-08-13 |
mouse |
| Anna Jeong, Michael Won. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology. Current neurology and neuroscience reports. vol 16. issue 12. 2017-08-07. PMID:27815691. |
in particular, tuberous sclerosis complex (tsc) is a genetic disorder resulting from overactivation of the mtor pathway, and pharmacologic therapy with mtor inhibitors has emerged as a viable treatment option for the systemic manifestations of the disease. |
2017-08-07 |
2023-08-13 |
Not clear |
| David N Franz, Elena Belousova, Steven Sparagana, E Martina Bebin, Michael D Frost, Rachel Kuperman, Olaf Witt, Michael H Kohrman, J Robert Flamini, Joyce Y Wu, Paolo Curatolo, Petrus J de Vries, Noah Berkowitz, Julie Niolat, Sergiusz Jóźwia. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PloS one. vol 11. issue 6. 2017-07-24. PMID:27351628. |
everolimus, a mammalian target of rapamycin (mtor) inhibitor, has demonstrated efficacy in treating subependymal giant cell astrocytomas (segas) and other manifestations of tuberous sclerosis complex (tsc). |
2017-07-24 |
2023-08-13 |
Not clear |
| Tao Yang, Linnan Zhu, Yanhua Zhai, Qingjie Zhao, Jianxia Peng, Hongbing Zhang, Zhongzhou Yang, Lianfeng Zhang, Wenjun Ding, Yong Zha. TSC1 controls IL-1β expression in macrophages via mTORC1-dependent C/EBPβ pathway. Cellular & molecular immunology. vol 13. issue 5. 2017-07-18. PMID:27593484. |
the tuberous sclerosis complex 1 (tsc1) is a tumor suppressor that inhibits the mammalian target of rapamycin (mtor), which serves as a key regulator of inflammatory responses after bacterial stimulation in monocytes, macrophages, and primary dendritic cells. |
2017-07-18 |
2023-08-13 |
mouse |
| Katarzyna Switon, Katarzyna Kotulska, Aleksandra Janusz-Kaminska, Justyna Zmorzynska, Jacek Jaworsk. Molecular neurobiology of mTOR. Neuroscience. vol 341. 2017-07-03. PMID:27889578. |
changes in mtor activity are often observed in nervous system diseases, including genetic diseases (e.g., tuberous sclerosis complex, pten-related syndromes, neurofibromatosis, and fragile x syndrome), epilepsy, brain tumors, and neurodegenerative disorders (alzheimer's disease, parkinson's disease, and huntington's disease). |
2017-07-03 |
2023-08-13 |
Not clear |
| Krzysztof Sadowski, Katarzyna Kotulska, Sergiusz Jóźwia. Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacological reports : PR. vol 68. issue 3. 2017-06-27. PMID:26891243. |
management of side effects of mtor inhibitors in tuberous sclerosis patients. |
2017-06-27 |
2023-08-13 |
Not clear |
| Krzysztof Sadowski, Katarzyna Kotulska, Sergiusz Jóźwia. Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacological reports : PR. vol 68. issue 3. 2017-06-27. PMID:26891243. |
mtor inhibitors represent a relatively new therapeutic option in the management of patients affected by tuberous sclerosis complex (tsc). |
2017-06-27 |
2023-08-13 |
Not clear |
| Li Ding, Yue Yin, Lingling Han, Yin Li, Jing Zhao, Weizhen Zhan. TSC1-mTOR signaling determines the differentiation of islet cells. The Journal of endocrinology. vol 232. issue 1. 2017-06-26. PMID:27754935. |
neurogenin3-driven deletion of tuberous sclerosis complex 1 (tsc1) activated mechanistic target of rapamycin complex 1 (mtorc1) measured by the upregulation of mtor and s6 phosphorylation in islet cells. |
2017-06-26 |
2023-08-13 |
mouse |
| Shogo Wada, Michael Neinast, Cholsoon Jang, Yasir H Ibrahim, Gina Lee, Apoorva Babu, Jian Li, Atsushi Hoshino, Glenn C Rowe, James Rhee, José A Martina, Rosa Puertollano, John Blenis, Michael Morley, Joseph A Baur, Patrick Seale, Zoltan Aran. The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue. Genes & development. vol 30. issue 22. 2017-06-14. PMID:27913603. |
cytoplasmic retention of tfe3 by mtor is sensitive to ambient amino acids, is independent of growth factor and tuberous sclerosis complex (tsc) signaling, is driven by ragc/d, and is separable from canonical mtor signaling to s6k. |
2017-06-14 |
2023-08-13 |
Not clear |
| Lijuan Zhang, Sally Justus, Yu Xu, Tamara Pluchenik, Chun-Wei Hsu, Jin Yang, Jimmy K Duong, Chyuan-Sheng Lin, Yading Jia, Alexander G Bassuk, Vinit B Mahajan, Stephen H Tsan. Reprogramming towards anabolism impedes degeneration in a preclinical model of retinitis pigmentosa. Human molecular genetics. vol 25. issue 19. 2017-06-09. PMID:27516389. |
we conditionally ablated the tuberous sclerosis complex 1 (tsc1) gene, an mtor inhibitor, in the rods of the pde6b |
2017-06-09 |
2023-08-13 |
human |
| Kenneth A Myers, Ingrid E Scheffe. DEPDC5 as a potential therapeutic target for epilepsy. Expert opinion on therapeutic targets. vol 21. issue 6. 2017-06-05. PMID:28406046. |
tuberous sclerosis is the prototypic mtor genetic syndrome with epilepsy, however gator1 gene mutations have recently been shown to cause lesional and non-lesional focal epilepsy. |
2017-06-05 |
2023-08-13 |
Not clear |
| Kenneth A Myers, Ingrid E Scheffe. DEPDC5 as a potential therapeutic target for epilepsy. Expert opinion on therapeutic targets. vol 21. issue 6. 2017-06-05. PMID:28406046. |
we review the epilepsy types associated with mtor overactivity, including tuberous sclerosis, polyhydramnios megalencephaly symptomatic epilepsy, cortical dysplasia, non-lesional focal epilepsy and post-traumatic epilepsy. |
2017-06-05 |
2023-08-13 |
Not clear |
| Vinod K Srivastava, Jill K Hiney, William L Dee. Manganese-Stimulated Kisspeptin Is Mediated by the IGF-1/Akt/Mammalian Target of Rapamycin Pathway in the Prepubertal Female Rat. Endocrinology. vol 157. issue 8. 2017-05-31. PMID:27309941. |
downstream to akt, centrally administered mn increased tuberous sclerosis complex 2 (p < .05), ras homolog enriched in brain (p < .01), mtor (p < .05), and kisspeptin (p < .05). |
2017-05-31 |
2023-08-13 |
rat |
| Filipe Palavra, Conceição Robalo, Flávio Rei. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. Oxidative medicine and cellular longevity. vol 2017. 2017-05-23. PMID:28386314. |
recent advances and challenges of mtor inhibitors use in the treatment of patients with tuberous sclerosis complex. |
2017-05-23 |
2023-08-13 |
Not clear |
| Jian Yang, Paulina A Samsel, Kalin Narov, Ashley Jones, Daniel Gallacher, John Gallacher, Julian R Sampson, Ming Hong She. Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2 Neoplasia (New York, N.Y.). vol 19. issue 2. 2017-05-04. PMID:28092822. |
combination of everolimus with sorafenib for solid renal tumors in tsc2 tuberous sclerosis (tsc) is an inherited tumor syndrome caused by mutations in tsc1 or tsc2 that lead to aberrant activation of mtor and development of tumors in multiple organs including the kidneys. |
2017-05-04 |
2023-08-13 |
Not clear |
| Jacqueline A French, John A Lawson, Zuhal Yapici, Hiroko Ikeda, Tilman Polster, Rima Nabbout, Paolo Curatolo, Petrus J de Vries, Dennis J Dlugos, Noah Berkowitz, Maurizio Voi, Severine Peyrard, Diana Pelov, David N Fran. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet (London, England). vol 388. issue 10056. 2017-04-10. PMID:27613521. |
everolimus, a mammalian target of rapamycin (mtor) inhibitor, has been used for various benign tumours associated with tuberous sclerosis complex. |
2017-04-10 |
2023-08-13 |
Not clear |